CE
CELC.US Celcuity LLC
- Market cap
- USD 3.15B
- P/E
- -
- P/B
- 78.90x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CELC.US undervalued?
Graham numberThe Graham number of Celcuity LLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Celcuity LLC fundamental analysis
No fundamental analysis for Celcuity LLC yet.
Celcuity LLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth …
Full company profileCelcuity LLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Celcuity LLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 154K | 0.00 |
| Gross Profit | -73.1K | -105K | -223K | -339K | -386K | -303K | -211K | -143K | -130K | -167K | - |
| Operating Income | -3.33M | -5.95M | -7.93M | -7.81M | -9.56M | -28.4M | -39.4M | -66.2M | -113M | -172M | -259M |
| EBITDA | -3.26M | -5.85M | -7.71M | -7.47M | -9.17M | -28.0M | -38.1M | -58.3M | -101M | -160M | -229M |
| Net Income | -3.31M | -6.25M | -7.48M | -7.36M | -9.47M | -29.6M | -40.4M | -63.8M | -112M | -177M | -273M |
| EPS | -0.49 | -0.84 | -0.74 | -0.72 | -0.92 | -2.21 | -2.62 | -2.69 | -2.83 | -3.79 | -4.96 |
| Balance Sheet | |||||||||||
| Total Assets | 6.06M | 32.0M | 26.0M | 20.3M | 13.0M | 85.9M | 176M | 191M | 245M | 467M | 727M |
| Total Liabilities | 445K | 578K | 682K | 983K | 1.25M | 17.2M | 41.9M | 51.5M | 130M | 366M | 801M |
| Shareholders' Equity | 5.61M | 31.4M | 25.3M | 19.3M | 11.7M | 68.7M | 134M | 140M | 116M | 101M | -74.0M |
| Cash & Short-term Investments | 5.86M | 24.2M | 24.9M | 18.8M | 11.7M | 84.3M | 169M | 181M | 235M | 441M | 643M |
| Total Debt | - | - | 25.6K | 256K | 262K | 14.9M | 35.2M | 37.4M | 98.0M | 195M | 755M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.89M | -4.95M | -6.08M | -6.00M | -7.15M | -20.3M | -36.0M | -53.8M | -83.5M | -153M | -236M |
| Capital Expenditure | 40.9K | 240K | 630K | 380K | 89.4K | 81.9K | 159K | 97.6K | 250K | 249K | 775K |
| Free Cash Flow | -2.93M | -5.19M | -6.71M | -6.38M | -7.24M | -20.4M | -36.2M | -53.9M | -83.7M | -154M | -236M |
| Ratios | |||||||||||
| ROE | -59.0% | -19.9% | -29.5% | -38.1% | -81.0% | -43.1% | -30.2% | -45.6% | -96.7% | -176.1% | - |
| ROA | -54.7% | -19.6% | -28.7% | -36.3% | -73.1% | -34.5% | -23.0% | -33.4% | -45.6% | -37.9% | -37.6% |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | -114,962.3% | - |
| Debt to Equity | - | - | 0.00x | 0.01x | 0.02x | 0.22x | 0.26x | 0.27x | 0.85x | 1.94x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Celcuity LLC dividends
Celcuity LLC has not paid dividends in the last 9 fiscal years.
Who owns Celcuity LLC
- Insiders 11.00%
- Institutions 89.00%
- Public & others 0.00%
- Shares outstanding 48.9M
- Free float 29.9M
Top funds holding CELC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.40M | 2.86% | +0.30% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.28M | 2.62% | +2.68% | Oct 2026 |
| iShares Russell 2000 ETF | 975K | 1.99% | 0.00% | Oct 2026 |
| Fidelity Select Biotechnology | 479K | 0.98% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 421K | 0.86% | +0.15% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 361K | 0.74% | -0.38% | Oct 2026 |
| FullerThaler Behavioral Sm-Cp Gr R6 | 350K | 0.72% | 0.00% | Jun 2026 |
| American Century Small Cap Growth Inv | 339K | 0.69% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 224K | 0.46% | +1.13% | Sep 2026 |
| Hood River Small-Cap Growth Instl | 223K | 0.46% | 0.00% | Jun 2026 |
| Schwab US Small-Cap ETF™ | 219K | 0.45% | +0.23% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 196K | 0.40% | -19.47% | Jun 2026 |
| Fidelity Extended Market Index | 189K | 0.39% | +1.66% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 187K | 0.38% | +0.02% | Aug 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 179K | 0.37% | 0.00% | Sep 2026 |
| Artisan International Small-Mid Investor | 175K | 0.36% | -38.72% | Sep 2026 |
| Belfius Equities Cure C Cap | 169K | 0.35% | 0.00% | Apr 2026 |
| Voya Small Cap Growth I | 169K | 0.34% | +1.99% | Sep 2026 |
| AB Small Cap Growth A | 128K | 0.26% | -2.51% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 125K | 0.25% | 0.00% | Sep 2026 |
Top institutions holding CELC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 7.92M | 16.18% | 0.00% | Jun 2026 |
| venBio Select Advisor LLC | 3.40M | 6.95% | +0.74% | Jun 2026 |
| RTW INVESTMENTS, LLC | 3.30M | 6.75% | +8.73% | Jun 2026 |
| Perceptive Advisors LLC | 3.20M | 6.53% | +2.24% | Jun 2026 |
| BlackRock Inc | 3.02M | 6.17% | +11.33% | Jun 2026 |
| State Street Corp | 1.96M | 4.00% | +28.75% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.87M | 3.83% | +5.12% | Jun 2026 |
| NEA Management Company, LLC | 1.71M | 3.50% | -25.16% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.70M | 3.48% | +32.70% | Jun 2026 |
| Bank of America Corp | 1.47M | 3.01% | +105.97% | Jun 2026 |
| Deerfield Management Co | 1.45M | 2.97% | -15.34% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.33M | 2.73% | -0.83% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1.31M | 2.69% | +25.20% | Jun 2026 |
| The Toronto-Dominion Bank | 1.26M | 2.57% | +42.59% | Jun 2026 |
| Geode Capital Management, LLC | 1.11M | 2.27% | +24.76% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.03M | 2.10% | -19.85% | Jun 2026 |
| Wellington Management Company LLP | 907K | 1.85% | +111.35% | Jun 2026 |
| The Goldman Sachs Group Inc | 870K | 1.78% | +13.79% | Jun 2026 |
| Point72 Asset Management, L.P. | 651K | 1.33% | +132.20% | Jun 2026 |
| Hood River Capital Management LLC | 628K | 1.28% | 0.00% | Jun 2026 |
Celcuity LLC company profile
- Company name
- Celcuity LLC
- Ticker
- CELC.US
- Exchange
- USA Stocks
- Listed since
- Sep 20, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 155
- Fiscal year end
- December
- Address
- 2800 Campus Drive, Minneapolis, MN, United States, 55441
- Phone
- (763) 392-0123
- Website
- celcuity.com
About Celcuity LLC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Celcuity LLC management
9- Mr. Brian F. SullivanCo-Founder, Chairman & CEO · born 1962
- Dr. Lance G. Laing Ph.D.Co-Founder, Chief Science Officer, VP, Secretary & Director · born 1962
- Ms. Vicky Hahne CPAChief Financial Officer · born 1966
- Ms. Jodi SieversHead of Investor Relations & Corporate Communications
- Mr. Brent Eilefson J.D.General Counsel & Chief Compliance Officer
- Ms. Sheri SmithActing Head of Clinical Operations
- Mr. Igor Gorbatchevsky M.D.Chief Medical Officer
- Mr. Eldon C. Mayer III, M.B.A.Chief Commercial Officer · born 1961
- Mr. Byron Robinson J.D., Ph.D.Chief Strategy Officer · born 1965